CASI Pharma Pays $11.5 Million for China Rights to Three Spectrum Drugs

CASI Pharmaceuticals, formerly known as EntreMed, in-licensed China rights to three cancer products from Spectrum Pharma in exchange for a 20% stake in CASI and a $1.5 million promissory note. CASI has a market capitalization of almost $48 million, giving the 20% stake a value of close to $10 million and the entire deal a total value of $11.5 million. The transaction contains no provisions for milestones or royalties. Both companies are based in the US, though CASI is primarily focused on the China market and maintains a Beijing operation. More details.... Stock Symbols: (NSDQ: CASI) (NSDQ: SPPI) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.